CoChat

The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease

Open access

The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.

Abstract

A longitudinal molecular model of the development and progression of nonalcoholic fatty liver disease (NAFLD) over time is lacking. We have recently validated a high fat/sugar water-induced animal (an isogenic strain of C57BL/6 J:129S1/SvImJ mice) model of NAFLD that closely mimics most aspects of human disease. The hepatic transcriptome of such mice with fatty liver (8 weeks), steatohepatitis with early fibrosis (16–24 weeks) and advanced fibrosis (52 weeks) after initiation of the diet was evaluated and compared to mice on chow diet. Fatty liver development was associated with transcriptional activation of lipogenesis, FXR-RXR, PPAR-α mediated lipid oxidation and oxidative stress pathways. With progression to steatohepatitis, metabolic pathway activation persisted with additional activation of IL-1/inhibition of RXR, granulocyte diapedesis/adhesion, Fc macrophage activation, prothrombin activation and hepatic stellate cell activation. Progression to advanced fibrosis was associated with dampening of metabolic, oxidative stress and cell stress related pathway activation but with further Fc macrophage activation, cell death and turnover and activation of cancer-related networks. The molecular progression of NAFLD involves a metabolic perturbation which triggers subsequent cell stress and inflammation driving cell death and turnover. Over time, inflammation and fibrogenic pathways become dominant while in advanced disease an inflammatory-oncogenic profile dominates.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-017-17370-6

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Changes in metabolic pathways. Heat maps resulting from hierarchical clustering and box plots with averages for genes implicated in (A) de novo lipogenesis (11 genes averaged), (B) Fatty acid β-oxidation (8 genes averaged), (C) Sterol biosynthesis (22 genes averaged) or (D) FXR-RXR signaling (14 genes averaged) pathways with a fold-change greater than ±1.5 from WD SW liver samples as compared to CD NW at 8, 24 and 52 weeks or from liver tumors at 52 weeks as compared to WD SW 52 weeks with a false discovery rate (FDR) <0.1. Boxes show 25th and 75th percentile, whiskers show 5th and 95th percentile, red line is the median average score, and blue dash line shows no change compared with CD NW at 8, 24 and 52 weeks or compared to WD SW 52 weeks for liver tumors.
Figure 1 Changes in metabolic pathways. Heat maps resulting from hierarchical clustering and box plots with averages for genes implicated in (A) de novo lipogenesis (11 genes averaged), (B) Fatty acid β-oxidation (8 genes averaged), (C) Sterol biosynthesis (22 genes averaged) or (D) FXR-RXR signaling (14 genes averaged) pathways with a fold-change greater than ±1.5 from WD SW liver samples as compared to CD NW at 8, 24 and 52 weeks or from liver tumors at 52 weeks as compared to WD SW 52 weeks with a false discovery rate (FDR) <0.1. Boxes show 25th and 75th percentile, whiskers show 5th and 95th percentile, red line is the median average score, and blue dash line shows no change compared with CD NW at 8, 24 and 52 weeks or compared to WD SW 52 weeks for liver tumors.CC BY · PubMed Central
Figure 2 Changes in cell stress-related pathways. Heat maps resulting from hierarchical clustering and box plots with averages for genes implicated in (A) Peroxisome (30 genes averaged), (B) Nrf2-mediated oxidative stress (37 genes averaged), (C) Proteasome (48 genes averaged), (D) Mitochondrial dysfunctions (28 genes averaged), (E) Unfolded protein response (15 genes averaged) and (F) Autophagy (6 genes averaged) signaling pathways with a fold-change greater than ±1.5 from WD SW liver samples as compared to CD NW at 8, 24 and 52 weeks or from liver tumors at 52 weeks as compared to WD SW 52 weeks with a false discovery rate (FDR) <0.1. Boxes show 25th and 75th percentile, whiskers show 5th and 95th percentile, red line is the median average score, and blue dash line shows no change compared with CD NW at 8, 24 and 52 weeks or compared to WD SW 52 weeks for liver tumors.
Figure 2 Changes in cell stress-related pathways. Heat maps resulting from hierarchical clustering and box plots with averages for genes implicated in (A) Peroxisome (30 genes averaged), (B) Nrf2-mediated oxidative stress (37 genes averaged), (C) Proteasome (48 genes averaged), (D) Mitochondrial dysfunctions (28 genes averaged), (E) Unfolded protein response (15 genes averaged) and (F) Autophagy (6 genes averaged) signaling pathways with a fold-change greater than ±1.5 from WD SW liver samples as compared to CD NW at 8, 24 and 52 weeks or from liver tumors at 52 weeks as compared to WD SW 52 weeks with a false discovery rate (FDR) <0.1. Boxes show 25th and 75th percentile, whiskers show 5th and 95th percentile, red line is the median average score, and blue dash line shows no change compared with CD NW at 8, 24 and 52 weeks or compared to WD SW 52 weeks for liver tumors.CC BY · PubMed Central
Figure 3 Changes in apoptosis pathways. Heat maps resulting from hierarchical clustering and box plots with averages for genes implicated in apoptosis pathways (25 genes averaged) with a fold-change greater than ±1.5 from WD SW liver samples as compared to CD NW at 8, 24 and 52 weeks or from liver tumors at 52 weeks as compared to WD SW 52 weeks with a false discovery rate (FDR) <0.1. Boxes show 25th and 75th percentile, whiskers show 5th and 95th percentile, red line is the median average score, and blue dash line shows no change compared with CD NW at 8, 24 and 52 weeks or compared to WD SW 52 weeks for liver tumors.
Figure 3 Changes in apoptosis pathways. Heat maps resulting from hierarchical clustering and box plots with averages for genes implicated in apoptosis pathways (25 genes averaged) with a fold-change greater than ±1.5 from WD SW liver samples as compared to CD NW at 8, 24 and 52 weeks or from liver tumors at 52 weeks as compared to WD SW 52 weeks with a false discovery rate (FDR) <0.1. Boxes show 25th and 75th percentile, whiskers show 5th and 95th percentile, red line is the median average score, and blue dash line shows no change compared with CD NW at 8, 24 and 52 weeks or compared to WD SW 52 weeks for liver tumors.CC BY · PubMed Central
Figure 4 Changes in inflammatory pathways. Heat maps resulting from hierarchical clustering and box plots with averages for genes implicated in (A) TLR signaling (12 genes averaged), (B) Fcgr-mediated phagocytosis (18 genes averaged), (C) INFγ signaling (58 genes averaged), (D) Inflammasome (4 genes averaged) pathways with a fold-change greater than ±1.5 from WD SW liver samples as compared to CD NW at 8, 24 and 52 weeks or from liver tumors at 52 weeks as compared to WD SW 52 weeks with a false discovery rate (FDR) <0.1. Boxes show 25th and 75th percentile, whiskers show 5th and 95th percentile, red line is the median average score, and blue dash line shows no change compared with CD NW at 8, 24 and 52 weeks or compared to WD SW 52 weeks for liver tumors.
Figure 4 Changes in inflammatory pathways. Heat maps resulting from hierarchical clustering and box plots with averages for genes implicated in (A) TLR signaling (12 genes averaged), (B) Fcgr-mediated phagocytosis (18 genes averaged), (C) INFγ signaling (58 genes averaged), (D) Inflammasome (4 genes averaged) pathways with a fold-change greater than ±1.5 from WD SW liver samples as compared to CD NW at 8, 24 and 52 weeks or from liver tumors at 52 weeks as compared to WD SW 52 weeks with a false discovery rate (FDR) <0.1. Boxes show 25th and 75th percentile, whiskers show 5th and 95th percentile, red line is the median average score, and blue dash line shows no change compared with CD NW at 8, 24 and 52 weeks or compared to WD SW 52 weeks for liver tumors.CC BY · PubMed Central
Figure 5 Changes in fibrosis pathways. Heat maps resulting from hierarchical clustering and box plots with averages for genes implicated in fibrosis pathways (26 genes averaged) with a fold-change greater than ±1.5 from WD SW liver samples as compared to CD NW at 8, 24 and 52 weeks or from liver tumors at 52 weeks as compared to WD SW 52 weeks with a false discovery rate (FDR) <0.1. Boxes show 25th and 75th percentile, whiskers show 5th and 95th percentile, red line is the median average score, and blue dash line shows no change compared with CD NW at 8, 24 and 52 weeks or compared to WD SW 52 weeks for liver tumors.
Figure 5 Changes in fibrosis pathways. Heat maps resulting from hierarchical clustering and box plots with averages for genes implicated in fibrosis pathways (26 genes averaged) with a fold-change greater than ±1.5 from WD SW liver samples as compared to CD NW at 8, 24 and 52 weeks or from liver tumors at 52 weeks as compared to WD SW 52 weeks with a false discovery rate (FDR) <0.1. Boxes show 25th and 75th percentile, whiskers show 5th and 95th percentile, red line is the median average score, and blue dash line shows no change compared with CD NW at 8, 24 and 52 weeks or compared to WD SW 52 weeks for liver tumors.CC BY · PubMed Central
Figure 6 Changes in cell proliferation and oncogenic pathways. Heat maps resulting from hierarchical clustering and box plots with averages for genes implicated in (A) Proliferation (41 genes averaged), (B) Cancer pathways (51 genes averaged), (C) TGFβ signaling (2 genes averaged), (D) Wnt-β catenin (3 genes averaged) pathways with a fold-change greater than ±1.5 from WD SW liver samples as compared to CD NW at 8, 24 and 52 weeks or from liver tumors at 52 weeks as compared to WD SW 52 weeks with a false discovery rate (FDR) <0.1. Boxes show 25th and 75th percentile, whiskers show 5th and 95th percentile, red line is the median average score, and blue dash line shows no change compared with CD NW at 8, 24 and 52 weeks or compared to WD SW 52 weeks for liver tumors.
Figure 6 Changes in cell proliferation and oncogenic pathways. Heat maps resulting from hierarchical clustering and box plots with averages for genes implicated in (A) Proliferation (41 genes averaged), (B) Cancer pathways (51 genes averaged), (C) TGFβ signaling (2 genes averaged), (D) Wnt-β catenin (3 genes averaged) pathways with a fold-change greater than ±1.5 from WD SW liver samples as compared to CD NW at 8, 24 and 52 weeks or from liver tumors at 52 weeks as compared to WD SW 52 weeks with a false discovery rate (FDR) <0.1. Boxes show 25th and 75th percentile, whiskers show 5th and 95th percentile, red line is the median average score, and blue dash line shows no change compared with CD NW at 8, 24 and 52 weeks or compared to WD SW 52 weeks for liver tumors.CC BY · PubMed Central
Figure 7 The molecular progression of NAFLD. First, a metabolic perturbation which triggers subsequent cell stress and inflammation driving cell death and turnover. Over time, inflammation and fibrogenic pathways become dominant while in advanced disease an inflammatory-oncogenic profile dominates. Upper part of the figure: Representative images of liver histology from DIAMOND mice at 8 (NAFL), 24 (Stage 0–2 fibrosis) and 52 weeks (Stage 3 fibrosis with HCC) (H&E or Sirius Red; original magnification, ×10).
Figure 7 The molecular progression of NAFLD. First, a metabolic perturbation which triggers subsequent cell stress and inflammation driving cell death and turnover. Over time, inflammation and fibrogenic pathways become dominant while in advanced disease an inflammatory-oncogenic profile dominates. Upper part of the figure: Representative images of liver histology from DIAMOND mice at 8 (NAFL), 24 (Stage 0–2 fibrosis) and 52 weeks (Stage 3 fibrosis with HCC) (H&E or Sirius Red; original magnification, ×10).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Cited by

See all 66

Metadata

Authors
Cazanave, S., Podtelezhnikov, A., Jensen, K., Seneshaw, M., Kumar, D. P., Min, H.-K., Santhekadur, P. K., Banini, B., Mauro, A. G., M. Oseini, A., Vincent, R., Tanis, K. Q., Webber, A. L., Wang, L., Bedossa, P., Mirshahi, F., & Sanyal, A. J.
Affiliations
  • Virginia Commonwealth University (US)
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Corresponding author
  • Cazanave, Sophie
  • Sanyal, Arun J.
Venue
Scientific Reports
Published
2017-12-08
Volume
7
Issue
1
Pages
17193-17193
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2771222944
Cited by
66
References
56
Citations by year
2026: 5 · 2025: 5 · 2024: 6 · 2023: 9 · 2022: 6 · 2021: 10 · 2020: 12 · 2019: 12 · 2018: 1
FWCI
5.36
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases (R03DK081450, T32DK007150, R01DK081410)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
Keywords
non-alcoholic fatty liver disease, disease progression, liver transcriptome, steatohepatitis, liver fibrosis, lipogenesis, PPARα, oxidative stress, IL-1 signaling, hepatic stellate cells, inflammation, cell death, mouse model
MeSH terms
Animals, Liver Cirrhosis, Male, Mice, Inbred C57BL, Signal Transduction, Disease Progression, Gene Expression Profiling, Mice, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease. https://app.cochat.ai/papers/10.1038/s41598-017-17370-6
The paper
Cazanave, S., Podtelezhnikov, A., Jensen, K., Seneshaw, M., Kumar, D. P., Min, H.-K., Santhekadur, P. K., Banini, B., Mauro, A. G., M. Oseini, A., Vincent, R., Tanis, K. Q., Webber, A. L., Wang, L., Bedossa, P., Mirshahi, F., & Sanyal, A. J. (2017). The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease. Scientific Reports. https://doi.org/10.1038/s41598-017-17370-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.